SCHEMBL4603533

SCHEMBL4603533

O=C(CCc1ccncc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.61
CYP2C19 P33261 2/20 0.61
ALDH1A1 P00352 2/20 0.61
PLOD2 O00469 1/20 0.61
PLOD3 O60568 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
HPGD P15428 1/20 0.61
PLOD1 Q02809 1/20 0.61
HIF1A Q16665 1/20 0.61
RAB9A P51151 3/20 0.59
TDP1 Q9NUW8 3/20 0.59
NPC1 O15118 2/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
NPY5R Q15761 1/20 0.57
LMNA P02545 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11304333 0.93 TDP1 (0.62) CYP1A2CYP2C19ALDH1A1PLOD2PLOD3
SCHEMBL5092579 0.89 TDP1 (0.77) CYP1A2CYP2C19ALDH1A1PLOD2PLOD3
SCHEMBL15524969 0.86 TDP1 (0.77) CYP2C19ALDH1A1CYP3A4HPGDRAB9A
SCHEMBL30572 0.86 TDP1 (0.77) CYP2C19ALDH1A1CYP3A4HPGDRAB9A
SCHEMBL28251466 0.86 TDP1 (0.77) CYP2C19ALDH1A1CYP3A4HPGDRAB9A
SCHEMBL9195700 0.84 ALDH1A1 (0.77) CYP1A2CYP2C19ALDH1A1PLOD2PLOD3
Hydrochloric Acid SCHEMBL27556767 0.84 TDP1 (0.74) CYP2C19ALDH1A1CYP3A4HPGDRAB9A
SCHEMBL1157353 0.81 ALDH1A1 (0.66) CYP1A2CYP2C19ALDH1A1PLOD2PLOD3
SCHEMBL7539034 0.81 GPR84 (0.51) CYP3A4RAB9ANPC1LMNAL3MBTL1
SCHEMBL3247901 0.81 PLOD2 (0.65) CYP1A2CYP2C19ALDH1A1PLOD2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287492-A1 Alkylpyridyl Quinolines as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-20 US claimed
CN-113816899-B Method for generating ketone or ester by catalytic oxidation of substituted aromatic compound with carbon material 浙江大学衢州研究院 2023-04-14 CN disclosed
CN-113816899-A Method for generating ketone or ester by catalytic oxidation of substituted aromatic compound with carbon material 浙江大学衢州研究院 2021-12-21 CN disclosed
US-20080287492-A1 Alkylpyridyl Quinolines as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-20 US disclosed
US-20080287492-A1 Alkylpyridyl Quinolines as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-20 US disclosed
US-20080287492-A1 Alkylpyridyl Quinolines as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-20 US disclosed
EP-1915361-A1 ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS AstraZeneca AB (SE) 2008-04-30 EP disclosed
WO-2007018466-A1 ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed
WO-2007018466-A1 ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287492-A1 Alkylpyridyl Quinolines as Nk3 Receptor Modulators ADORA3, KCNA3, TACR1 CYP1A2 756/4885CYP2C19 568/4885ALDH1A1 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.